U.S. Markets closed
  • S&P 500

    4,356.45
    -53.68 (-1.22%)
     
  • Dow 30

    34,297.73
    -66.77 (-0.19%)
     
  • Nasdaq

    13,539.29
    -229.61 (-1.67%)
     
  • Russell 2000

    2,025.05
    +37.13 (+1.87%)
     
  • Crude Oil

    85.15
    +1.84 (+2.21%)
     
  • Gold

    1,848.70
    +7.00 (+0.38%)
     
  • Silver

    23.89
    +0.09 (+0.36%)
     
  • EUR/USD

    1.1303
    -0.0027 (-0.2374%)
     
  • 10-Yr Bond

    1.7830
    +0.0360 (+2.06%)
     
  • Vix

    29.95
    +1.10 (+3.81%)
     
  • GBP/USD

    1.3508
    +0.0017 (+0.1297%)
     
  • USD/JPY

    113.8910
    -0.0690 (-0.0605%)
     
  • BTC-USD

    36,767.38
    -210.57 (-0.57%)
     
  • CMC Crypto 200

    835.36
    +24.76 (+3.05%)
     
  • FTSE 100

    7,371.46
    -122.67 (-1.64%)
     
  • Nikkei 225

    27,131.34
    -457.06 (-1.66%)
     

2 Reasons to Buy Exact Sciences Stock, and 1 Reason to Sell

·4 min read
2 Reasons to Buy Exact Sciences Stock, and 1 Reason to Sell
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • EXAS

Thanks to its highly sensitive tests that can detect cancer earlier, less invasively, and with more confidence than the alternatives, Exact Sciences (NASDAQ: EXAS) has already made a home for itself in the oncology screening market. Its operations are perennially unprofitable, not to mention that its pace of revenue growth is often meandering. Are these blemishes dealbreakers, or are they bumps in the road along the trajectory of a growth stock?